HC Wainwright Reaffirms “Buy” Rating for Praxis Precision Medicines (NASDAQ:PRAX)

Posted by Brenda Bartman on May 26th, 2026

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $1,245.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 262.38% from the company’s current price.

PRAX has been the subject of a number of other research reports. Needham & Company LLC reissued a “buy” rating and issued a $510.00 price objective on shares of Praxis Precision Medicines in a research note on Tuesday, April 14th. Robert W. Baird set a $433.00 price objective on Praxis Precision Medicines and gave the company an “outperform” rating in a research note on Friday, February 20th. Wedbush raised their price objective on Praxis Precision Medicines from $130.00 to $166.00 and gave the company an “underperform” rating in a research note on Friday, May 8th. Truist Financial raised their target price on Praxis Precision Medicines from $700.00 to $715.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. Finally, Raymond James Financial started coverage on Praxis Precision Medicines in a report on Friday, April 10th. They issued a “strong-buy” rating and a $815.00 target price on the stock. Four analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $592.67.

Get Our Latest Analysis on PRAX

Praxis Precision Medicines Stock Performance

Shares of Praxis Precision Medicines stock opened at $343.56 on Tuesday. Praxis Precision Medicines has a 52 week low of $35.21 and a 52 week high of $358.76. The stock has a 50 day moving average price of $322.09 and a two-hundred day moving average price of $290.36. The stock has a market capitalization of $9.58 billion, a PE ratio of -25.70 and a beta of 2.76.

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($3.20) EPS for the quarter, beating analysts’ consensus estimates of ($3.58) by $0.38. Research analysts forecast that Praxis Precision Medicines will post -14.79 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PRAX. Orbis Allan Gray Ltd bought a new position in shares of Praxis Precision Medicines in the fourth quarter valued at approximately $369,946,000. Janus Henderson Group PLC lifted its holdings in Praxis Precision Medicines by 17.2% during the fourth quarter. Janus Henderson Group PLC now owns 3,240,086 shares of the company’s stock worth $954,834,000 after acquiring an additional 476,227 shares during the period. Barclays PLC boosted its position in Praxis Precision Medicines by 592.6% in the fourth quarter. Barclays PLC now owns 530,751 shares of the company’s stock worth $156,434,000 after purchasing an additional 454,114 shares during the last quarter. Baker BROS. Advisors LP boosted its position in Praxis Precision Medicines by 63.4% in the fourth quarter. Baker BROS. Advisors LP now owns 1,126,488 shares of the company’s stock worth $332,021,000 after purchasing an additional 437,000 shares during the last quarter. Finally, Perceptive Advisors LLC boosted its position in Praxis Precision Medicines by 27.6% in the fourth quarter. Perceptive Advisors LLC now owns 1,995,986 shares of the company’s stock worth $588,297,000 after purchasing an additional 431,432 shares during the last quarter. Institutional investors own 67.84% of the company’s stock.

About Praxis Precision Medicines

(Get Free Report)

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.